

References

I-88

1. Neupogen (Filgrastim) [package insert]. Thousand Oaks, CA. Amgen Inc. Revised 07/2015.
2. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Version 1.2013.
3. National Comprehensive Cancer Network (NCCN). NCCN Drugs & Biologic Compendium®. 2013.
4. Fine S, Koo M, Gill T, et al. The use of granulocyte colony-stimulating factors in a Canadian outpatient setting. *Curr Oncol*. 2014;21(2):e229-240.
5. Crobu D, Spinetti G, Schrepfer R, et al. Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen®. *BMC Pharmacology and Toxicology*. 2014;15:7.
6. Cubells DA, Roig CB, Orozco EJ, et al. Effectiveness of daily versus non-daily granulocyte colony-stimulating factors in patients with solid tumours undergoing chemotherapy: a multivariate analysis of data from current practice. *European Journal of Cancer Care*. 2013;22:400-412
7. 8. Iqbal MP, Burney IA. Low doses of colony-stimulating factors lead to resolution of neutropenia in cancer patients through increased levels of dihydrofolate reductase. *Pak J. Pharm Sci*. 2014;27(2):245-248.
8. Schuster A, Klotz M, Schwab T. et al. Granulocyte-colony stimulating factor: A new player for the enteric nervous system. *Cell Tissue Res*. 2014;355:35–48.
9. Granix® (Tbo-filgrastim) subcutaneous injection [package insert]. North Wales, PA. Teva Pharmaceuticals USA Inc. 2/2017.
10. National Comprehensive Cancer Network (NCCN). NCCN Drugs & Biologics Compendium®. Tbo-filgrastim. 2018.
11. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in Myeloid growth factors. Version 1.2018.
12. Smith TJ, Bohlke K, Lyman GH, et al. American Society of Clinical Oncology. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol*. 2015;33(28):3199-3212.
13. Pettengell R, Bias P, Mueller U, et al. Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor. *Supportive Care In Cancer: Official Journal Of The Multinational Association Of Supportive Care In Cancer*. 2016;24(6):2677-2684.

14. Gascón P, Apro M, Gascón P, et al. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). *Supportive Care In Cancer*. 2016;24(2):911-925.
15. Brito M, Esteves S, André R, et al. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: A non-interventional cohort study. *Supportive Care In Cancer: Official Journal Of The Multinational Association Of Supportive Care In Cancer*.2016;24(2):597-603.
16. Raedler L. Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States. *American Health & Drug Benefits*. 2016;9:150-154.
17. Leukine® (Sargramostim) subcutaneous injection, intravenous [package insert]. Bridgewater, NJ. Sanofi-Aventis US LLC. Revised 3/2018.
18. Neulasta® (Pegfilgrastim) subcutaneous injection [package insert]. Thousand Oaks, CA. Amgen Inc. Revised 12/2017.
19. Zarxio™ (Filgrastim-sndz) subcutaneous injection and intravenous injection [package insert]. Princeton, NJ. Sandoz Inc. Revised 3/2016.
20. National Comprehensive Cancer Network (NCCN). Filgrastim. NCCN Drugs and Biologics Compendium®. 2018.
21. National Comprehensive Cancer Network (NCCN). Filgrastim-sndz. NCCN Drugs and Biologics Compendium®. 2018.
22. National Comprehensive Cancer Network (NCCN). Pegfilgrastim. NCCN Drugs and Biologics Compendium®. 2018.
23. National Comprehensive Cancer Network (NCCN). Sargramostim. NCCN Drugs and Biologics Compendium®. 2018.
24. Filgrastim. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2018.
25. Filgrastim-sndz. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2018.
26. Pegfilgrastim. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2018.
27. Tbo-filgrastim. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2018.
28. Sargramostim. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2018.
29. MICROMEDEX®SOLUTIONS Compendia. 2018. Filgrastim.
30. MICROMEDEX®SOLUTIONS Compendia. 2018. Filgrastim-sndz.
31. MICROMEDEX®SOLUTIONS Compendia. 2018. Pegfilgrastim.

32. MICROMEDEX®SOLUTIONS Compendia. 2018. Tbo-filgrastim.
33. MICROMEDEX®SOLUTIONS Compendia. 2018. Sargramostim.
34. Douglas AG, Schwab P, Lane D, Kennedy K, Slabaugh SL, and Bowe A. A comparison of brand and biosimilar granulocyte-colony stimulating factors for prophylaxis of chemotherapy-induced febrile neutropenia. *J Manage Care Spec Pharm*. 2017;23(12):1221-1226.
35. Weycker D, Li X, Tzivelekis S, Atwood M, Garcia J, Li Y, et al. Burden of chemotherapy-induced febrile neutropenia hospitalizations in US clinical practice, by use and patterns of prophylaxis with colony-stimulating factor. *Support Care Cancer*. 2017;25:439-447.
36. Lyman GH, Abella E, and Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. *Critical Reviews in Oncology/Hematology*. 2014;90:190-199.
37. Fulphila™ (Pegfilgrastim-jmdb) subcutaneous injection [package insert]. Zurich, Switzerland. Mylan GmbH. Revised 6/2018.
38. Filgrastim-aafi (Nivestym™) for subcutaneous or intravenous injection [package insert]. Lake Forest, IL. Hospira Inc., a Pfizer Company. Revised 07/2018.